{"id":634,"date":"2017-07-23T12:58:46","date_gmt":"2017-07-23T19:58:46","guid":{"rendered":"http:\/\/www.useriscontent.com\/blog\/?p=634"},"modified":"2019-07-21T21:30:26","modified_gmt":"2019-07-22T04:30:26","slug":"dea-manufacturing-caps-for-oxycodone-and-hydrocodone-2001-2017","status":"publish","type":"post","link":"https:\/\/www.useriscontent.com\/blog\/2017\/07\/23\/dea-manufacturing-caps-for-oxycodone-and-hydrocodone-2001-2017\/","title":{"rendered":"DEA Manufacturing Caps for Oxycodone and Hydrocodone 2001-2017"},"content":{"rendered":"<p>The D.E.A (Drug Enforcement Agency) sets caps on the amounts of schedule 1 and 2 drugs that manufacturers can legally produce each year. \u00a0 I was curious to see how the caps had changed over time and it was relatively simple to discover via the Federal Register. Considering all the lawsuits now targeting pharmaceutical manufacturers like Purdue, Johnson &amp; Johnson, Allergen and Teva, I wonder if the D.E.A could also be considered an actor in the current opioid epidemic.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-649 size-full\" src=\"http:\/\/www.useriscontent.com\/blog\/..\/media\/by-default-2017-07-23-at-4.29.18-PM.jpg\" alt=\"\" width=\"796\" height=\"491\" srcset=\"https:\/\/www.useriscontent.com\/blog\/..\/media\/by-default-2017-07-23-at-4.29.18-PM.jpg 796w, https:\/\/www.useriscontent.com\/blog\/..\/media\/by-default-2017-07-23-at-4.29.18-PM-300x185.jpg 300w, https:\/\/www.useriscontent.com\/blog\/..\/media\/by-default-2017-07-23-at-4.29.18-PM-768x474.jpg 768w\" sizes=\"auto, (max-width: 709px) 85vw, (max-width: 909px) 67vw, (max-width: 984px) 61vw, (max-width: 1362px) 45vw, 600px\" \/><\/p>\n<p>&nbsp;<\/p>\n<blockquote><p>&#8230;final aggregate production quotas for the following controlled substances, <strong>expressed in grams<\/strong> of anhydrous acid or base, be established as follows:<\/p><\/blockquote>\n<p>(Not sure what 'conversion' means in this sense, but I think it has to do with converting one substance to another, i.e. one drug could be converted into another.)<\/p>\n<p>2001<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2001\/10\/15\/01-25761\/controlled-substances-final-revised-aggregate-production-quotas-for-2001\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2001\/10\/15\/01-25761\/controlled-substances-final-revised-aggregate-production-quotas-for-2001<\/a><br \/>\nOxycodone (for sale) 46,680,000<br \/>\nOxycodone (for conversion) 449,000<br \/>\nHydrocodone (for sale) 23,825,000<br \/>\nHydrocodone (for conversion) 18,000,000<\/p>\n<p>2002<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2002\/09\/20\/02-23876\/controlled-substances-final-revised-aggregate-production-quotas-for-2002\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2002\/09\/20\/02-23876\/controlled-substances-final-revised-aggregate-production-quotas-for-2002<\/a><br \/>\nOxycodone (for sale) 34,482,000<br \/>\nOxycodone (for conversion) 1,100,000<br \/>\nHydrocodone (for sale) 25,702,000<br \/>\nHydrocodone (for conversion) 2,500,000<\/p>\n<p>2003<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2003\/09\/30\/03-24653\/controlled-substances-final-revised-aggregate-production-quotas-for-2003\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2003\/09\/30\/03-24653\/controlled-substances-final-revised-aggregate-production-quotas-for-2003<\/a><br \/>\nOxycodone (for sale) 41,182,000<br \/>\nOxycodone (for conversion) 700,000<br \/>\nHydrocodone (for sale) 30,622,000<br \/>\nHydrocodone (for conversion) 1,500,000<\/p>\n<p>2004<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2004\/11\/16\/04-25340\/controlled-substances-final-revised-aggregate-production-quotas-for-2004\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2004\/11\/16\/04-25340\/controlled-substances-final-revised-aggregate-production-quotas-for-2004<\/a><br \/>\nOxycodone (for sale) 49,200,000<br \/>\nOxycodone (for conversion) 920,000<br \/>\nHydrocodone (for sale) 34,000,000<br \/>\nHydrocodone (for conversion) 1,500,000<\/p>\n<input type='hidden' bg_collapse_expand='6a7c386a30daa9071192703' value='6a7c386a30daa9071192703'><input type='hidden' id='bg-show-more-text-6a7c386a30daa9071192703' value='Show More'><input type='hidden' id='bg-show-less-text-6a7c386a30daa9071192703' value='Show Less'><button id='bg-showmore-action-6a7c386a30daa9071192703' class='bg-showmore-plg-button bg-blue-button bg-arrow '   style=\" color:inherit;\">Show More<\/button><div id='bg-showmore-hidden-6a7c386a30daa9071192703' ><\/p>\n<p>2005<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2005\/11\/09\/05-22287\/controlled-substances-final-revised-aggregate-production-quotas-for-2005\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2005\/11\/09\/05-22287\/controlled-substances-final-revised-aggregate-production-quotas-for-2005<\/a><br \/>\nOxycodone (for sale) 50,490,000<br \/>\nOxycodone (for conversion) 920,000<br \/>\nHydrocodone (for sale) 37,604,000<br \/>\nHydrocodone (for conversion) 1,500,000<\/p>\n<p>2006<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2006\/10\/19\/E6-17524\/controlled-substances-final-revised-aggregate-production-quotas-for-2006\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2006\/10\/19\/E6-17524\/controlled-substances-final-revised-aggregate-production-quotas-for-2006<\/a><br \/>\nOxycodone (for sale) 56,000,000 g<br \/>\nOxycodone (for conversion) 4,610,000 g<br \/>\nHydrocodone (for sale) 42,000,000 g<br \/>\nHydrocodone (for conversion) 1,500,000 g<\/p>\n<p>2007<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2007\/08\/24\/E7-16730\/controlled-substances-final-revised-aggregate-production-quotas-for-2007\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2007\/08\/24\/E7-16730\/controlled-substances-final-revised-aggregate-production-quotas-for-2007<\/a><br \/>\nOxycodone (for sale) 70,000,000<br \/>\nOxycodone (for conversion) 3,100,000<br \/>\nHydrocodone (for sale) 46,000,000<br \/>\nHydrocodone (for conversion) 1,500,000<\/p>\n<p>2008<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2008\/11\/12\/E8-26798\/controlled-substances-final-revised-aggregate-production-quotas-for-2008\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2008\/11\/12\/E8-26798\/controlled-substances-final-revised-aggregate-production-quotas-for-2008<\/a><br \/>\nOxycodone (for sale) 70,000,000<br \/>\nOxycodone (for conversion) 4,820,000<br \/>\nHydrocodone (for sale) 55,000,000<br \/>\nHydrocodone (for conversion) 1,500,000<\/p>\n<p>2009<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2009\/10\/21\/E9-25274\/controlled-substances-final-revised-aggregate-production-quotas-for-2009\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2009\/10\/21\/E9-25274\/controlled-substances-final-revised-aggregate-production-quotas-for-2009<\/a><br \/>\nOxycodone (for sale) 94,000,000 g<br \/>\nOxycodone (for conversion) 4,500,000 g<br \/>\nHydrocodone (for sale) 55,500,000 g<\/p>\n<p>2010<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2010\/09\/14\/2010-22785\/controlled-substances-final-revised-aggregate-production-quotas-for-2010\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2010\/09\/14\/2010-22785\/controlled-substances-final-revised-aggregate-production-quotas-for-2010<\/a><br \/>\nOxycodone (for sale) 105,500,000 g<br \/>\nOxycodone (for conversion) 5,600,000 g<br \/>\nHydrocodone 55,000,000 g<\/p>\n<p>2011<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2011\/12\/09\/2011-31621\/controlled-substances-final-adjusted-aggregate-production-quotas-for-2011\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2011\/12\/09\/2011-31621\/controlled-substances-final-adjusted-aggregate-production-quotas-for-2011<\/a><br \/>\nOxycodone (for sale) 98,000,000 g<br \/>\nOxycodone (for conversion) 5,600,000 g<br \/>\nHydrocodone (for sale) 59,000,000 g<\/p>\n<p>2012<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2012\/09\/10\/2012-22128\/controlled-substances-final-adjusted-aggregate-production-quotas-for-2012\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2012\/09\/10\/2012-22128\/controlled-substances-final-adjusted-aggregate-production-quotas-for-2012<\/a><br \/>\nOxycodone (for sale) 105,200,000 g<br \/>\nOxycodone (for conversion) 7,600,000 g<br \/>\nHydrocodone (for sale) 79,700,000 g<\/p>\n<p>2013<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2013\/08\/07\/2013-19046\/final-adjusted-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2013\/08\/07\/2013-19046\/final-adjusted-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and<\/a><br \/>\nOxycodone (for sale) 153,750,000 g<br \/>\nOxycodone (for conversion) 10,250,000 g<br \/>\nHydrocodone (for sale) 99,625,000 g<\/p>\n<p>2014<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2014\/08\/25\/2014-20137\/final-adjusted-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2014\/08\/25\/2014-20137\/final-adjusted-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and<\/a><br \/>\nOxycodone (for sale) 149,375,000<br \/>\nOxycodone (for conversion) 9,250,000<br \/>\nHydrocodone (for sale) 99,625,000<br \/>\nHydrocodone (for conversion) 137,500<\/p>\n<p>2015<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2015\/09\/16\/2015-23199\/final-adjusted-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2015\/09\/16\/2015-23199\/final-adjusted-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and<\/a><br \/>\nOxycodone (for sale) 141,375,000<br \/>\nOxycodone (for conversion) 8,350,000<br \/>\nHydrocodone (for sale) 99,625,000<br \/>\nHydrocodone (for conversion) 137,500<\/p>\n<p>2016<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2016\/10\/25\/2016-25696\/final-adjusted-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2016\/10\/25\/2016-25696\/final-adjusted-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and<\/a><br \/>\nOxycodone (for sale) 139,150,000<br \/>\nOxycodone (for conversion) 5,000,000<br \/>\nHydrocodone (for sale) 86,000,000<br \/>\nHydrocodone (for conversion) 177,500<\/p>\n<p>2017<br \/>\n<a href=\"https:\/\/www.federalregister.gov\/documents\/2016\/10\/05\/2016-23988\/established-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.federalregister.gov\/documents\/2016\/10\/05\/2016-23988\/established-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment<\/a><br \/>\nOxycodone (for sale) 108,510,000<br \/>\nOxycodone (for conversion) 2,610,000<br \/>\nHydrocodone (for sale) 58,410,000<br \/>\nHydrocodone (for conversion) 122,000<\/p>\n<p><\/div>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The D.E.A (Drug Enforcement Agency) sets caps on the amounts of schedule 1 and 2 drugs that manufacturers can legally produce each year. \u00a0 I was curious to see how the caps had changed over time and it was relatively simple to discover via the Federal Register. Considering all the lawsuits now targeting pharmaceutical manufacturers &hellip; <a href=\"https:\/\/www.useriscontent.com\/blog\/2017\/07\/23\/dea-manufacturing-caps-for-oxycodone-and-hydrocodone-2001-2017\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> \"DEA Manufacturing Caps for Oxycodone and Hydrocodone 2001-2017\"<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29],"tags":[363,362,365,367,364,366],"class_list":["post-634","post","type-post","status-publish","format-standard","hentry","category-from-the-field","tag-d-e-a","tag-german-lopez","tag-manufacturing-caps","tag-matt-yglesias","tag-opioid-epidemic","tag-the-weeds"],"_links":{"self":[{"href":"https:\/\/www.useriscontent.com\/blog\/wp-json\/wp\/v2\/posts\/634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.useriscontent.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.useriscontent.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.useriscontent.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.useriscontent.com\/blog\/wp-json\/wp\/v2\/comments?post=634"}],"version-history":[{"count":18,"href":"https:\/\/www.useriscontent.com\/blog\/wp-json\/wp\/v2\/posts\/634\/revisions"}],"predecessor-version":[{"id":765,"href":"https:\/\/www.useriscontent.com\/blog\/wp-json\/wp\/v2\/posts\/634\/revisions\/765"}],"wp:attachment":[{"href":"https:\/\/www.useriscontent.com\/blog\/wp-json\/wp\/v2\/media?parent=634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.useriscontent.com\/blog\/wp-json\/wp\/v2\/categories?post=634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.useriscontent.com\/blog\/wp-json\/wp\/v2\/tags?post=634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}